Anti-Amyloid Fibril antibody [mOC87] - BSA and Azide free
- BOND RX™ Validated
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(0 Publication)
Rabbit Recombinant Monoclonal Amyloid-beta precursor protein antibody. Carrier free. Suitable for IHC-P, IHC-FrFl, Dot and reacts with Human, Mouse, Synthetic peptide samples.
View Alternative Names
A4, AD1, APP, Amyloid-beta precursor protein, ABPP, APPI, Alzheimer disease amyloid A4 protein homolog, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta (A4) precursor protein, Amyloid-beta A4 protein, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, CVAP, PN-II
- IHC-FrFl
Collaborator
Immunohistochemistry - Free Floating - Anti-Amyloid Fibril antibody [mOC87] - BSA and Azide free (AB251335)
This data was developed using ab201062, the same antibody clone in a different buffer formulation.
Immunohistochemical staining of human brain tissue from a patient with a diagnosis of Alzheimers disease, male, 81 years, 5 hour post mortem index, tangle stage 5, plaque stage B, mini mental status exam score 12. Sections were cut using a vibratome. No antigen retrieval was performed. Free floating sections were stained using ab201062 at a dilution of 50 ng/mL. The secondary antibody used was a biotinylated goat anti-rabbit at a dilution of 1/225, which was blocked with normal goat serum. The sample was visualized using ABC solution (1 hour incubation) followed by 1-4 minutes of DAB. The sample was mounted and allowed to dry overnight, followed by dehydration in increasingly concentrated ethanol solutions.
Image courtesy of Professor Charles Glabe, UC Irvine
- IHC-P
Lab
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Amyloid Fibril antibody [mOC87] - BSA and Azide free (AB251335)
This data was developed using ab201062, the same antibody clone in a different buffer formulation.
IHC image of beta Amyloid staining in human Alzheimer hippocampus formalin fixed paraffin embedded tissue section*, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab201062, 1μg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
- Dot
Supplier Data
Dot Blot - Anti-Amyloid Fibril antibody [mOC87] - BSA and Azide free (AB251335)
This data was developed using ab201062, the same antibody clone in a different buffer formulation.
Negative control (secondary ab only) :
Lane 1 : beta Amyloid (Aβ) 1-40.
Lane 2 : beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer : 5% NFDM/TBST.
Exposure time : 30 seconds.
- Dot
Supplier Data
Dot Blot - Anti-Amyloid Fibril antibody [mOC87] - BSA and Azide free (AB251335)
This data was developed using ab201062, the same antibody clone in a different buffer formulation.
Dot blot analysis of beta Amyloid 1-42 labeled with ab201062 at 1/8000 dilution.
Lane 1 : beta Amyloid (Aβ) 1-40.
Lane 2 : beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer : 5% NFDM/TBST.
Exposure time : 30 seconds.
Antibody reactivity was assessed using a dot blot, which is a non-quantitative method that maintains the native conformation of beta Amyloid. Beta Amyloid 1-40 and 1-42 peptides underwent the following aggregation conditions before being spotted onto a nitrocellulose membrane and detected using ab201062 :
Monomers : 0.3 mg of beta Amyloid peptide was dissolved in 30 μl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 μl of 1% SDS and boiled for five minutes.
Oligomers : 0.3 mg of beta Amyloid peptide was dissolved in 30 μl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 μl of 10 mM phosphate buffer pH 7.4 containing 0.02% sodium azide and incubated at room temperature for four days.
Fibrils : 0.3 mg of beta Amyloid peptide was dissolved in 1 ml 50% hexafluoroisopropanol (HFIP) with 0.02% sodium azide. It was then stirred constantly for nine days; the first seven with a cap on and the final two with the cap removed to allow evaporation of the HFIP. Fibrils were then sedimented at 20,000 rpm in a microcentrifuge for 20 minutes and resuspended in 1 ml of PBS + 0.02% sodium azide.
Related conjugates and formulations (1)
-
Anti-Amyloid Fibril antibody [mOC87] - Conformation-Specific
Reactivity data
You may be interested in:
Why is this recommended?
We recommend this product because it’s often used in the same experiment or related research.
We advise that you always check the datasheet to ensure it fits your experiments, or contact ourtechnical teamfor help.
Product details
ab251335 is the carrier-free version of ab201062.
This antibody was developed as part of a collaboration between Abcam and Professor Charles Glabe, UC Irvine.
ab251335 recognizes a generic epitope of amyloid fibrils and oligomers that is independent of linear sequence (Hatami et al 2014, PMID: 25281743). Its reactivity with AΒ monomer and oligomers is decreased or eliminated upon thermal denaturation at 100°C of AΒ in SDS sample buffer on western blots (Hatami et al 2014, PMID: 25281743).
For further information on the immunogen, please refer to Hatami et al 2014, PMID: 25281743 and <Kayed et al. 2007, PMID: 17897471.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The misfolding and accumulation of proteins into amyloid fibrils prove disruptive within cells. These aggregates often form as part of complex protein assemblies and interfere with normal cellular functions. This disruption further leads to cellular dysfunction and death. While commonly observed in neuronal cells where they are linked to neurodegenerative conditions amyloid fibrils can also appear in other tissues and organs suggesting multi-systemic implications.
Pathways
Scientists recognize amyloid fibrils for their involvement in the amyloidogenic pathways. These pathways often lead to the generation and accumulation of misfolded proteins. The amyloid precursor protein (APP) and presenilins play important roles in pathway processes associated with amyloid fibrils. In addition the fibrillar structures can influence calcium dysregulation and oxidative stress contributing to altered cellular homeostasis.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com